AstraZeneca lupus drug impresses in mid-stage trial

LONDON (Reuters) - AstraZeneca's experimental lupus drug anifrolumab significantly cut disease activity in a mid-stage clinical trial, boosting hopes for a medicine the company believes could become a…
Read the full story: Reuters: Health News